Predictive Factors of Osimertinib as Salvage Treatment for Metastatic EGFR T790M Positive Lung Adenocarcinoma

被引：0
|
作者：
Jang, S. H. [1 ]
Park, J. Y. [1 ]
Hwang, Y. I. [1 ]
Kim, H. Y. [2 ]
Seo, J. W. [3 ]
机构：
[1] Hallym Univ, Sacred Heart Hosp, Dept Pulm Allergy & Crit Care Med, Anyang, South Korea
[2] Hallym Univ, Sacred Heart Hosp, Dept Hematol Oncol, Anyang, South Korea
[3] Hallym Univ, Sacred Heart Hosp, Dept Pathtol, Anyang, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Osimertinib; resistance; predictive factor;
D O I：
10.1016/j.jtho.2019.08.1788
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-03
引用
收藏
页码：S830 / S830
页数：1
相关论文
共 50 条
  • [1] PREDICTIVE FACTORS OF OSIMERTINIB AS SALVAGE TREATMENT FOR METASTATIC EGFR T790M POSITIVE LUNG ADENOCARCINOMA
    Park, Ji Young
    Jang, Seung Hun
    Kim, Hwan Il
    Kim, Joo-Hee
    Park, Sunghoon
    Hwang, Yong Il
    Jung, Ki-Suck
    Seo, Jinwon
    RESPIROLOGY, 2019, 24 : 177 - 177
  • [2] Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
    Sakai, Hitomi
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Hasegawa, Yoshikazu
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    ESMO OPEN, 2017, 2
  • [3] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [4] Osimertinib or platinum-pemetrexed in EGFR T790M positive lung cancer
    Bernard-Tessier, A.
    ONCOLOGIE, 2017, 19 (5-6) : 203 - 204
  • [5] Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M
    Senoo, Satoru
    Ohashi, Kadoaki
    Nishii, Kazuya
    Hara, Naofumi
    Kano, Hirohisa
    Ninomiya, Kiichiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E140 - E142
  • [6] Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
    Zhang, Xiaoying
    GLOBAL MEDICAL GENETICS, 2021, 08 (04): : 133 - 134
  • [7] Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site
    Uematsu, Shinya
    ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [8] Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
    Liu, Yang
    Xiong, Zhi-Cheng
    Sun, Xin
    Sun, Li
    Zhang, Shu-Ling
    Ma, Jie-Tao
    Han, Cheng-Bo
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 2151 - 2163
  • [9] Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma
    Iams, W.
    Chae, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2249 - S2250
  • [10] Osimertinib in EGFR T790M-Positive Lung Cancer
    Nishino, Mizuki
    Hatabu, Hiroto
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (20): : 1992 - 1993
12345